DOL finalized a rule requiring pharmacy benefit managers to disclose fees and compensation to self-insured employers, including rebates and spread-pricing details, and allowing audits. It projects up to $22 billion in lower drug costs over a decade, praised by employer and pharmacy groups but criticized by a PBM group.